AbSci, the Vancouver, Wash.-based biotech startup that is developing an insulin-related technology, continues to experience healthy growth.
The company is in the process of doubling its space in downtown Vancouver to 11,000 square feet, or the entire floor of its building. And AbSci is hiring 14 more employees, for a total of 45 by the end of the year, said founder and CEO Sean McClain. The positions span the marketing and business development side of the business, along with the scientific.
